- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00555750
Sleep Loss and Mechanisms of Impaired Glucose Metabolism
The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia
The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S. Food and Drug Administration (FDA) for sale for the treatment of insomnia. It is marketed in the United States as LUNESTA.
Main Hypothesis: Primary insomnia is associated with impairments of glucose metabolism that can be reversed by two months of eszopiclone for the primary insomnia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital, Division of Sleep Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 25-55
- Complaint of insomnia of at least 6 months duration
- DSM-IV diagnosis of Primary Insomnia
- Sleep diary: mean Total Sleep Time < 6 hours and a mean total wake time (sleep latency + wake after sleep onset) of greater than 60 minutes (in previous 14 days as recorded on sleep diary)
- A willingness to comply with study procedures
- If of child-bearing potential, using a medically-accepted method of birth control, including abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method, and intrauterine device [IUD])
Exclusion Criteria:
- Current diagnosis of DSM-IV Axis I disorder other than Primary Insomnia
- Regular treatment (more than 1 time/week) with CNS active medication within 1 month of fist inpatient visit
- Treatment with medications that interfere with glucose metabolism including anti-diabetic medications or steroidal contraceptives
- Uncontrolled medical illness that would interfere with participation in the study
- Body Mass Index >32 or <19.8
- Current symptoms or diagnosis of any moderate to severe sleep disorder other than insomnia
- No menopausal or peri-menopausal symptoms that disrupt sleep
- Pregnant, lactating or planning to become pregnant
- Consumption of > 2 caffeinated beverages per day (including coffee, tea and/or other caffeine-containing beverages or food) during 3 weeks prior to the start of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: eszopiclone (3mg)
active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
|
3mg tablet, by mouth nightly 30 min before bed, for two months
Other Names:
|
Placebo Comparator: placebo
identical placebo tablet by mouth nightly 30 min before bed
|
inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test
Time Frame: baseline and 2 months post-treatment
|
Difference in glucose tolerance (Kg) in response to insulin-modified intravenous glucose tolerance test.
Glucose tolerance was calculated as the slope of the natural log of declining glucose values from minute 5 to minute 19 post-infusion.
By convention, this negative slope is multiplied by -1, in other words, expressed as a rate of disposal.
|
baseline and 2 months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Insulin Response to Glucose (AIRg)
Time Frame: baseline and 2 months post-treatment
|
Change over two months in 1st phase Insulin secretion
|
baseline and 2 months post-treatment
|
Change in Insulin Sensitivity (SI)
Time Frame: baseline and 2 months post-treatment
|
Insulin sensitivity index (SI) "was defined in quantitative terms as the effect of insulin to catalyse the disappearance of glucose from plasma." [R. Bergman, Horm Res 2005;64(suppl 3):8-15]. SI calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA) |
baseline and 2 months post-treatment
|
Change in Glucose Effectiveness (SG)
Time Frame: baseline and 2 months post-treatment
|
Glucose effectiveness was defined as "the ability of glucose itself to enhance its own disappearance independent of an increment in insulin." [R. Bergman, Horm Res 2005;64(suppl 3):8-15]. SG calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA) |
baseline and 2 months post-treatment
|
Change in HbA1c Levels
Time Frame: baseline and 2 months post-treatment
|
Difference in HbA1c levels following two months treatment with eszopiclone versus placebo
|
baseline and 2 months post-treatment
|
Pre-Treatment Leptin Levels
Time Frame: baseline
|
Leptin Levels prior to two months treatment with eszopiclone or placebo, measure after an overnight fast
|
baseline
|
Post-treatment Leptin Levels
Time Frame: two months post-treatment
|
Leptin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast
|
two months post-treatment
|
Pre-treatment Ghrelin Levels
Time Frame: baseline
|
Ghrelin levels prior to two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast
|
baseline
|
Post-treatment Ghrelin Levels
Time Frame: 2 months post-treatment
|
Ghrelin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast
|
2 months post-treatment
|
Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)
Time Frame: baseline and 2 months post-treatment
|
At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery including the Karolinska Sleepiness Scale (KSS) every three hours during wake periods.
KSS is a single-item scale of sleepiness on a scale from 1 ("very alert") to 9 ("very sleepy, fighting sleep, an effort to keep awake").
Subjective sleepiness was defined as mean deviation from baseline KSS.
|
baseline and 2 months post-treatment
|
Change in Mean Lapses of Attention
Time Frame: baseline and 2 months post-treatment
|
At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery every three hours during wake periods.
The battery included the Psychomotor Vigilance Task (PVT).
The PVT involved a 10-minute visual reaction time (RT) performance test in which the subject was instructed to maintain the fastest possible RT to a simple visual stimulus.
Lapses of attention refer to the number of times the subject failed to respond to the signal within 500ms.
Mean lapses per test across 6 tests given a 4 hour intervals during normal waking hours (and not during the IVGTT) during the 30-hr were compared for the post-treatment visit as the absolute deviation from the baseline mean lapses/test.
|
baseline and 2 months post-treatment
|
Change in Total Sleep Time as Reported in Sleep Diaries
Time Frame: baseline and 2 months post-treatment
|
Total sleep time reported on sleep diaries prior to treatment with 3mg eszopiclone or placebo.
Change defined as baseline minus post-treatment).
|
baseline and 2 months post-treatment
|
Change in Total Sleep Time Measured by PSG
Time Frame: baseline and 2 months post-treatment
|
Change (baseline minus post-treatment) in total sleep time measured by polysomnography after two months treatment with 3mg eszopiclone or placebo
|
baseline and 2 months post-treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John W Winkelman, MD, PhD, Brigham and Women's Hospital
Publications and helpful links
General Publications
- Ayas NT, White DP, Al-Delaimy WK, Manson JE, Stampfer MJ, Speizer FE, Patel S, Hu FB. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care. 2003 Feb;26(2):380-4. doi: 10.2337/diacare.26.2.380.
- Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, Hu FB. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med. 2003 Jan 27;163(2):205-9. doi: 10.1001/archinte.163.2.205.
- King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 Sep;21(9):1414-31. doi: 10.2337/diacare.21.9.1414.
- Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16. doi: 10.1001/jama.288.21.2709.
- Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999 Oct 23;354(9188):1435-9. doi: 10.1016/S0140-6736(99)01376-8.
- Belenky G, Wesensten NJ, Thorne DR, Thomas ML, Sing HC, Redmond DP, Russo MB, Balkin TJ. Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study. J Sleep Res. 2003 Mar;12(1):1-12. doi: 10.1046/j.1365-2869.2003.00337.x.
- Beck-Nielsen H, Henriksen JE, Alford F, Hother-Nielson O. In vivo glucose metabolism, insulin secretion and, insulin action in Europids with non-insulin-dependent diabetes mellitus (NIDDM) and their first-degree relatives. Diabet Med. 1996 Sep;13(9 Suppl 6):S78-84.
- Boyne MS, Saudek CD. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care. 1999 Apr;22 Suppl 3:C45-53.
- Buxton OM, Spiegel K and Van Cauter E. Modulation of endocrine function and metabolism by sleep and sleep loss. In: Sleep Medicine, edited by Lee-Chiong M, Carskadon M and Sateia M. Philadelphia: Hanley & Belfus, Inc., 2002, p. 59-69.
- Buysse DJ, Jarrett DB, Miewald JM, Kupfer DJ, Greenhouse JB. Minute-by-minute analysis of REM sleep timing in major depression. Biol Psychiatry. 1990 Nov 15;28(10):911-25. doi: 10.1016/0006-3223(90)90571-i.
- Czeisler CA, Winkelman JW and Richardson GS. Disorders of sleep and circadian rhythms. In: Harrison's Principles of Internal Medicine, edited by Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL and Jameson JL. New York: McGraw-Hill,Inc., 2000, p. 1-78.
- Dijk DJ, Duffy JF, Czeisler CA. Circadian and sleep/wake dependent aspects of subjective alertness and cognitive performance. J Sleep Res. 1992 Jun;1(2):112-7. doi: 10.1111/j.1365-2869.1992.tb00021.x.
- Dinges DF, Kribbs NB, Bates BL and Carlin MM. A very brief probed-recall memory task: Sensitivity to sleep loss. Sleep Res 22: 330, 1993.
- Dinges DF and Powell JW. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behavior Research Methods, Instruments & Computers 17: 652-655, 1985.
- Gillberg M, Kecklund G, Akerstedt T. Relations between performance and subjective ratings of sleepiness during a night awake. Sleep. 1994 Apr;17(3):236-41. doi: 10.1093/sleep/17.3.236.
- Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, Nieto FJ. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005 Apr 25;165(8):863-7. doi: 10.1001/archinte.165.8.863.
- Hoddes E, Dement WC and Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiol 9: 150, 1971.
- King H, Zimmet P. Trends in the prevalence and incidence of diabetes: non-insulin-dependent diabetes mellitus. World Health Stat Q. 1988;41(3-4):190-6.
- Nilsson PM, Roost M, Engstrom G, Hedblad B, Berglund G. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care. 2004 Oct;27(10):2464-9. doi: 10.2337/diacare.27.10.2464.
- Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 1997 Oct;154(10):1417-23. doi: 10.1176/ajp.154.10.1417.
- Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004 Dec 7;141(11):846-50. doi: 10.7326/0003-4819-141-11-200412070-00008.
- Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep. 2003 Mar 15;26(2):117-26. doi: 10.1093/sleep/26.2.117. Erratum In: Sleep. 2004 Jun 15;27(4):600.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BWH-HRC-2005-P-001997
- M01RR002635 (U.S. NIH Grant/Contract)
- ESRC0004 (Other Grant/Funding Number: Sunovion previously Sepracor Inc)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Insomnia
-
Midnight Pharma, LLCCompletedChronic Primary InsomniaUnited States
-
IWK Health CentreUnknownPrimary Insomnia | Nonorganic InsomniaCanada
-
Oregon Health and Science UniversityCompletedPrimary Insomnia | Psychophysiological InsomniaUnited States
-
University of RochesterSanofi-SynthelaboCompletedInsomnia | Primary Insomnia | Psychophysiologic InsomniaUnited States
-
University of UtahEvans Army Community HospitalCompletedPrimary Insomnia | Secondary InsomniaUnited States
-
US Department of Veterans AffairsCompletedInsomnia | Primary Insomnia | Secondary InsomniaUnited States
-
University of WashingtonUnknownChronic Insomnia | Insomnia, Primary
-
Jack Edinger, PhDMerck Sharp & Dohme LLCCompletedInsomnia | Primary Insomnia | Chronic InsomniaUnited States
-
University of PittsburghCompletedInsomnia Chronic | Insomnia, PrimaryUnited States
-
Eli Lilly and CompanyCompletedAn Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia (SLUMBER)Primary Insomnia | Secondary InsomniaUnited States
Clinical Trials on eszopiclone
-
Eisai Co., Ltd.Completed
-
Eisai Co., Ltd.Completed
-
SunovionCompletedInsomnia | Attention Deficit Hyperactivity DisorderUnited States
-
SunovionCompletedInsomnia | Attention Deficit Hyperactivity DisorderUnited States
-
Laboratorios Andromaco S.A.Completed
-
Beth Israel Deaconess Medical CenterTerminatedDiabetes | Glucose Intolerance | Prediabetes | PrediabeticUnited States
-
SunovionCompletedGeneralized Anxiety DisorderUnited States
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Mclean HospitalCompleted
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; SunovionCompleted
-
University of California, San DiegoAmerican Academy of Sleep MedicineRecruitingObstructive Sleep ApneaUnited States